BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16796781)

  • 1. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
    Stern DK; Lebwohl M
    J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides.
    Assaf C
    Dermatol Clin; 2008 Jan; 26 Suppl 1():21-2. PubMed ID: 18405182
    [No Abstract]   [Full Text] [Related]  

  • 5. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.
    Carretero-Margolis CD; Fivenson DP
    J Am Acad Dermatol; 2003 Feb; 48(2):275-6. PubMed ID: 12582402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follicular mycosis fungoides: successful treatment with oral bexarotene.
    Shistik G; Scalf LA; Fenske N; Glass LF
    J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
    Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
    J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
    Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
    Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denileukin diftitox plus total skin electron beam radiation in patients with treatment-refractory cutaneous T-cell Lymphoma (mycosis fungoides): report of four cases.
    Buder K; Müller PA; Beckmann G; Ugurel S; Bröcker EB; Becker JC
    Acta Derm Venereol; 2014 Jan; 94(1):94-6. PubMed ID: 23756575
    [No Abstract]   [Full Text] [Related]  

  • 10. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
    Kazin R; Bujanauskas P; Vonderheid EC
    J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S31-2. PubMed ID: 18191695
    [No Abstract]   [Full Text] [Related]  

  • 11. Bexarotene plus PUVA plus radiation combination therapy for mycosis fungoides.
    Coors E
    Dermatol Clin; 2008 Jan; 26 Suppl 1():33-5. PubMed ID: 18405185
    [No Abstract]   [Full Text] [Related]  

  • 12. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
    Huang J; Cowper S; Moss J; Girardi M
    J Drugs Dermatol; 2013 Apr; 12(4):487-9. PubMed ID: 23652902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A.
    Coors EA; Von den Driesch P
    Br J Dermatol; 2005 Jun; 152(6):1379-81. PubMed ID: 15949024
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimal combination with PUVA: rationale and clinical trial update.
    Stadler R
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):29-32. PubMed ID: 17474357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Juvenile mycosis fungoides treated with bexarotene and PUVA.
    Rodríguez-Vázquez M; García-Arpa M; González-García J
    Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denileukin diftitox.
    Saxon M
    Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jul; 6(7):757-60. PubMed ID: 17763605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
    Tsirigotis P; Pappa V; Papageorgiou S; Kapsimali V; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Stavrianeas N; Economopoulos T; Dervenoulas J
    Br J Dermatol; 2007 Jun; 156(6):1379-81. PubMed ID: 17459033
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel therapies for cutaneous T-cell lymphomas.
    Horwitz SM
    Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S187-92. PubMed ID: 19073526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choices in the treatment of cutaneous T-cell lymphoma.
    Hymes KB
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.